A new communications channel may on the agenda for the upcoming user fee negotiations to help complex generic sponsors deal with mid-assessment changes to their applications.
Robert Lionberger, director of the Office of Research and Standards in the US Food and Drug Administration's Office of Generic Drugs, said there is no "clear system set up for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?